On October 31, 2023 Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, reported that it will present new findings from a study leveraging its HYDRA platform that suggests a link between stromal hypersialylation and immunosuppression activity within the colorectal tumor microenvironment at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 38th Annual Meeting taking place in San Diego from November 1-5, 2023 (Press release, Palleon Pharmaceuticals, OCT 31, 2023, View Source [SID1234636603]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will include the specifics of the study which was conducted in collaboration with the University of Galway. The study revealed that both tumor cells and tumor-associated stromal cells are hypersialylated in the colorectal tumor environment. Additionally, removing sialic acids from stromal cells using an engineered human sialidase (EAGLE) reversed stromal cell-mediated immunosuppression in the co-culture of T cells and cancer-associated fibroblasts derived from colon cancer patients.
Details of the poster presentation are as follows:
Presentation Type: Poster Presentation (Abstract: #1438)
Title: Stromal hypersialylation within colorectal tumors contributes to immunosuppression of T cell adaptive immunity in the tumor microenvironment
Session: Poster Hall Session
Timing: November 4, 2023, 9:00 a.m. – 8:30 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center
The poster will appear on Palleon Pharmaceuticals’ website following the presentation.